-56%

est. 2Y upside i

HealthcareSeries B

Tandem is building the world's largest network of doctors, patients, and first-party data and applying AI to every step of bringing new therapies to market. Our first product ensures people get life-changing therapeutics as quickly and cheaply as possible. Founded by product leaders from Oscar Health.

Rank

#3351

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

The equity upside over 2 years is deeply negative across all scenarios due to the 20x entry multiple and critical incumbent threat.

Last updated: July 3, 2026

Bull (10%)-19%

10x exit multiple driven by IPO window and category leadership yields ~$970M exit; after $160M preferred, common recovers $810M, a 19% loss versus entry.

Base (45%)-58%

6x exit multiple converging to public comps gives ~$582M exit; after preferred, common gets $422M, a 57.8% loss.

Bear (45%)-87%

3x exit multiple from competitive compression yields ~$291M exit; after preferred, common recovers $131M, an 86.9% loss.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

16%

Total preferred stock of $160M represents 16% of the $1B valuation, creating a moderate overhang in downside scenarios.

Dilution Risk

low

The recent $123M Series B in May 2026 likely provides more than 2 years of runway, reducing near-term dilution risk.

Secondary Liquidity

none

No secondary market trades or implied valuation are reported; liquidity is expected only via IPO or acquisition.

Core 7 roles

Engineering 7 roles

Growth & GTM 6 roles

Operations & Scaling 4 roles

Data 2 roles

Product & Design 2 roles

View all 28 open roles at Tandem

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Tandem's data — designed to show you've done your homework.

  • 1

    How does the company plan to defend against Epic Systems embedding prior authorization for free, and what is the concrete competitive response?

  • 2

    What are the unit economics of a pharmaceutical partnership, and how scalable is the data monetization model given regulatory constraints?

  • 3

    Given the high current valuation, what is the realistic timeline to an IPO or acquisition, and what milestones would trigger a down round or equity impairment?

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.